| Reference | 1: Damjanov N, Karpati S, Kemeny L, Bakos N, Bobic B, Majdan M, Tlustochowicz W,
Vitek P, Dokoupilova E, Aldinc E, Szumski A. Efficacy and safety of etanercept in
psoriasis and psoriatic arthritis in the PRESTA study: Analysis in patients from
Central and Eastern Europe. J Dermatolog Treat. 2017 May 16:1-18. doi:
10.1080/09546634.2017.1329509. [Epub ahead of print] PubMed PMID: 28506134.</br>
2: Berthold E, Månsson B, Gullstrand B, Geborek P, Saxne T, Bengtsson AA, Kahn R.
Tumour necrosis factor-α/etanercept complexes in serum predict long-term efficacy
of etanercept treatment in seronegative rheumatoid arthritis. Scand J Rheumatol.
2017 May 9:1-5. doi: 10.1080/03009742.2017.1290822. [Epub ahead of print] PubMed
PMID: 28485187.</br>
3: Dougados M, van der Heijde D, Sieper J, Braun J, Citera G, Lenaerts J, van den
Bosch F, Wei JC, Pedersen R, Bonin R, Jones H, Marshall L, Logeart I, Vlahos B,
Bukowski JF, Maksymowych WP. Effects of Long-term Etanercept Treatment on
Clinical Outcomes and Objective Signs of Inflammation in Early Non-Radiographic
Axial Spondyloarthritis: 104-Week Results From the EMBARK Study. Arthritis Care
Res (Hoboken). 2017 May 8. doi: 10.1002/acr.23276. [Epub ahead of print] PubMed
PMID: 28482137.</br>
4: Ovejero-Benito MC, Prieto-Pérez R, Llamas-Velasco M, Belmonte C, Cabaleiro T,
Román M, Ochoa D, Talegón M, Saiz-Rodríguez M, Daudén E, Abad-Santos F.
Polymorphisms associated with etanercept response in moderate-to-severe plaque
psoriasis. Pharmacogenomics. 2017 May 4. doi: 10.2217/pgs-2017-0014. [Epub ahead
of print] PubMed PMID: 28470127.
</br>
5: Feldman SR, Zhao Y, Zhou H, Herrera V, Tian H, Li Y. Economic Impact of
Above-Label Dosing with Etanercept, Adalimumab, or Ustekinumab in Patients with
Psoriasis. J Manag Care Spec Pharm. 2017 May;23(5):583-589. doi:
10.18553/jmcp.2017.23.5.583. PubMed PMID: 28448778.</br>
6: Moots RJ, Xavier RM, Mok CC, Rahman MU, Tsai WC, Al-Maini MH, Pavelka K,
Mahgoub E, Kotak S, Korth-Bradley J, Pedersen R, Mele L, Shen Q, Vlahos B. The
impact of anti-drug antibodies on drug concentrations and clinical outcomes in
rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab:
Results from a multinational, real-world clinical practice, non-interventional
study. PLoS One. 2017 Apr 27;12(4):e0175207. doi: 10.1371/journal.pone.0175207.
eCollection 2017. PubMed PMID: 28448562; PubMed Central PMCID: PMC5407581.</br>
7: Mori M, Sugiyama N, Morishima Y, Sugiyama N, Kokubo T, Takei S, Yokota S.
Safety and effectiveness of etanercept for treatment of juvenile idiopathic
arthritis: Results from a postmarketing surveillance. Mod Rheumatol. 2017 Apr
27:1-7. doi: 10.1080/14397595.2017.1310704. [Epub ahead of print] PubMed PMID:
28448193.</br>
8: Lee H, Jung Y, Song S, Lee J, Shim H, Kang W, Kim E. DOSAGE AND DURATION OF
ETANERCEPT THERAPY FOR ANKYLOSING SPONDYLITIS: A META-ANALYSIS. Int J Technol
Assess Health Care. 2017 Apr 24:1-7. doi: 10.1017/S0266462317000150. [Epub ahead
of print] PubMed PMID: 28434410.</br>
9: Bouman C, van Herwaarden N, van den Hoogen F, van der Maas A, van den Bemt B,
den Broeder AA. Prediction of successful dose reduction or discontinuation of
adalimumab, etanercept, or infliximab in rheumatoid arthritis patients using
serum drug levels and antidrug antibody measurement. Expert Opin Drug Metab
Toxicol. 2017 Apr 24:1-7. doi: 10.1080/17425255.2017.1320390. [Epub ahead of
print] PubMed PMID: 28425772.</br>
10: Detrez I, Van Steen K, Segaert S, Gils A. The association between etanercept
serum concentration and psoriasis severity is highly age-dependent. Clin Sci
(Lond). 2017 Apr 18. pii: CS20170048. doi: 10.1042/CS20170048. [Epub ahead of
print] PubMed PMID: 28420676.
|
